IDDI starts Research on Statistical Method for individualization of Therapy
Clinical services provider International Drug Development Institute (IDDI) is forming a research collaborative into the use of a new statistical method called Generalized Pairwise Comparisons (GPC). The objective of the collaborative is to establish proof of the concept that the GPC method can complement traditional methods for the design, analysis and interpretation of clinical trial results in regard to accounting for multiple endpoints at once and ranked in order of priority. In addition to IDDI’s lead, the collaborative includes Bristol-Myers Squibb, the European Organization for Research and Treatment of Cancer (EORTC), the Université Catholique de Louvain and the University Hospital and Cancer Center of Lyon.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
